Prognose

Analytikernes gennemsnitlige kursmål er 5,62 € (+135,15 %). Medianen er 5,62 € (+135,15 %).

Køb	11
Behold	3
Sælg	0

Nyheder Til nyhedsfeedet

Ovid Therapeutics unveils pipeline strategy for neuronal hyperexcitability and KCC2 platform

Ovid Therapeutics presented at the H.C. Wainwright conference its focus strategy on brain disorders driven by neuronal hyperexcitability, centered on two lead programs: OV329 for epilepsy and OV4071, the first oral direct KCC2 activator. Management said OV329 shows a strong safety profile and is expected to report photosensitivity data in the coming months and phase II results in about a year; OV4071 is in phase I, a ketamine challenge is planned before year‑end, and a phase II program for acute schizophrenia is scheduled for mid‑2025. Financial figures were not discussed; management emphasized the platform ambitions, biomarker‑driven development and multiple near‑term proof‑of‑concept catalysts. » Mere på de.investing.com
Ovid Therapeutics emphasizes KCC2 program and epilepsy pipeline as value drivers

At the Cantor conference Ovid Therapeutics presented its two‑pillar strategy centered on the KCC2 program (OV4071) and the epilepsy pipeline (notably OV329), and views KCC2 as the main long‑term value driver if early human data confirm preclinical results. OV4071 is in phase I; a ketamine challenge and several biomarker studies are intended to link earlier animal data with human data. OV329 is being positioned to differentiate in focal-onset and pediatric epilepsies; proof‑of‑concept data and a phase II are planned for 2024/2025. Ovid also retains rights to milestone/license payments from Soticlestat, which represents additional upside without development risk. » Mere på de.investing.com
Ovid Therapeutics names Kevin Norrett chief business officer, promotes key executives

Ovid Therapeutics appointed Kevin Norrett as chief business officer to lead business development and strategic partnerships. Charles Carter was promoted to CFO, succeeding Jeffrey Rona who will remain a long-term advisor through 2027, and Victoria Fort was promoted to chief strategy officer. The company reported Q1 EPS of (12c), said development programs are on track, and expects to be well capitalized into 2029. » Mere på finance.yahoo.com

Virksomhedstal

I det seneste kvartal havde OVID THERAPEUTICS DL-,001 en omsætning på 642,26 t € og et nettoresultat på -13,15 mio. €

(EUR)	juni 2026	YoY
Omsætning	642,26 t	87,93 %
Bruttofortjeneste	642,26 t	87,93 %
Nettoresultat	-13,15 mio.	230,93 %
EBITDA	-13,48 mio.	246,47 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	434,45 mio. €
Antal aktier	186,64 mio.
Højeste/laveste i 52 uger	2,69 € - 0,97 €
Udbytte	Nej
Beta	0,25
P/E (PE Ratio)	-5,60
PEG (PEG Ratio)	0,16
K/I (PB Ratio)	0,95
P/S (PS Ratio)	317,16

Virksomhedsprofil

Ovid Therapeutics Inc. ist ein biopharmazeutisches Unternehmen, das wirksame Medikamente für Patienten und Familien mit neurologischen Erkrankungen in den Vereinigten Staaten entwickelt. Das Unternehmen entwickelt OV101, einen Arzneimittelkandidaten, der sich in der klinischen Phase 2A zur Behandlung des fragilen X-Syndroms befindet, OV329, einen GABA-Aminotransferase-Hemmer zur Behandlung von Anfällen im Zusammenhang mit tuberöser Sklerose und infantilen Spasmen, und OV350, ein kleines Molekül zur Behandlung von Epilepsien. Darüber hinaus entwickelt das Unternehmen OV882, eine Short-Hairpin-RNA-Gentherapie zur Behandlung des Angelman-Syndroms, und OV815 zur Behandlung von neurologischen Störungen im Zusammenhang mit der Kinesin-Protein-Familie. Das Unternehmen hat Lizenz- und Kooperationsvereinbarungen mit Healx, AstraZeneca AB, H. Lundbeck A/S und der Northwestern University sowie mit Marinus Pharmaceuticals, Inc. Das Unternehmen wurde im Jahr 2014 gegründet und hat seinen Hauptsitz in New York, New York.

Navn	OVID THERAPEUTICS DL-,001
CEO	Margaret Alexander
Hjemsted	New York City, ny USA
Websted	ovidrx.com
Sektor	Materialer
Branche	Kemikalier
Børsnotering	05.05.2017
Medarbejdere	23